- Home
- TNGX vs SVA Comparison
TNGX vs SVA Comparison
Compare TNGX & SVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNGX
- SVA
- Stock Information
- Founded
- TNGX 2014
- SVA N/A
- Country
- TNGX United States
- SVA
- Employees
- TNGX N/A
- SVA 3261
- Industry
- TNGX Biotechnology: Pharmaceutical Preparations
- SVA
- Sector
- TNGX Health Care
- SVA
- Exchange
- TNGX Nasdaq
- SVA NYSE
- Market Cap
- TNGX 351.2M
- SVA N/A
- IPO Year
- TNGX N/A
- SVA N/A
- Fundamental
- Price
- TNGX $6.01
- SVA $6.47
- Analyst Decision
- TNGX Strong Buy
- SVA
- Analyst Count
- TNGX 6
- SVA 0
- Target Price
- TNGX $12.20
- SVA N/A
- AVG Volume (30 Days)
- TNGX 2.7M
- SVA N/A
- Earning Date
- TNGX 08-06-2025
- SVA N/A
- Dividend Yield
- TNGX N/A
- SVA N/A
- EPS Growth
- TNGX N/A
- SVA N/A
- EPS
- TNGX N/A
- SVA N/A
- Revenue
- TNGX $40,990,000.00
- SVA N/A
- Revenue This Year
- TNGX N/A
- SVA N/A
- Revenue Next Year
- TNGX N/A
- SVA N/A
- P/E Ratio
- TNGX N/A
- SVA N/A
- Revenue Growth
- TNGX 10.09
- SVA N/A
- 52 Week Low
- TNGX $1.03
- SVA N/A
- 52 Week High
- TNGX $12.02
- SVA N/A
- Technical
- Relative Strength Index (RSI)
- TNGX 76.36
- SVA N/A
- Support Level
- TNGX $5.34
- SVA N/A
- Resistance Level
- TNGX $6.40
- SVA N/A
- Average True Range (ATR)
- TNGX 0.50
- SVA 0.00
- MACD
- TNGX -0.02
- SVA 0.00
- Stochastic Oscillator
- TNGX 84.08
- SVA 0.00
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
About SVA SINOVAC BIOTECH LTD
Sinovac Biotech Ltd is a China-based biopharmaceutical company that focuses on research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases including, without limitation, hepatitis A, hepatitis B, hand foot and mouth disease (HFMD) caused by EV71, seasonal influenza, H5N1 and H1N1 pandemic influenza, coronavirus, pneumococcus, poliomyelitis, varicella and mumps.